Plain-English translation of NCT06385236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two newer injectable asthma medications— and —in people whose asthma isn't well controlled with standard treatments. Researchers want to understand how your genes affect how you respond to these medications, so they can eventually predict which treatment will work best for each patient before they start taking it.
Current blood tests and biomarkers aren't good enough at predicting which patients will benefit from newer asthma drugs. This study uses advanced genetic testing to figure out the biology behind why some people respond well to a medication while others don't, which could lead to better, more personalized asthma care.
You likely qualify if…
You likely don't qualify if…
You would receive one of the two injectable medications through the study, starting with an initial injection followed by regular maintenance injections every 2–4 weeks. Before, during, and after each medication period, you would have blood tests and genetic testing to help researchers understand how your body responds. The study involves multiple visits to track how your asthma improves and to gather the genetic data that will help predict treatment response in future patients.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States